Research Topics
| FREDERICK LEWIS ALTICESummaryAffiliation: Yale University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Predictors of HIV infection among newly sentenced male prisonersF L Altice
Yale University AIDS Program, New Haven, Connecticut 06510 2283, USA
J Acquir Immune Defic Syndr Hum Retrovirol 18:444-53. 1998..The high prevalence of HIV-seronegative inmates with self-reported high-risk behaviors also suggests the importance of prisons as sites for the introduction of appropriate risk-reduction interventions...
Correlates of HIV infection among incarcerated women: implications for improving detection of HIV infectionFrederick L Altice
Yale University, School of Medecine, New Haven, CT 06510 2283, USA
J Urban Health 82:312-26. 2005..Alternative methods of facilitating more widespread HIV testing, such as saliva tests, rapid serologic tests, and more routine testing in high HIV-prevalence areas should be considered both for clinical and for public health benefits...
The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection preventionFrederick L Altice
AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT 06510, USA
Clin Infect Dis 43:S178-83. 2006..Dialogue among practitioners and policy makers in the HIV care and substance abuse communities will facilitate an effective expansion of buprenorphine and ensure that these beneficial outcomes are achieved...
Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: implications for program replicationFrederick L Altice
Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut 06510 2283, USA
Clin Infect Dis 38:S376-87. 2004..Moreover, DAART should incorporate enhanced elements such as convenience, flexibility, confidentiality, cues and reminders, responsive pharmacy and medical services, and specialized training for staff...
Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug usersFrederick L Altice
Yale University AIDS Program, New Haven, Connecticut 06510, USA
J Urban Health 80:416-27. 2003..In addition, it demonstrates that this population can benefit from this therapy with the support of a nontraditional, community-based health intervention...
Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugsFrederick L Altice
Department of Medicine, Section of Infectious Diseases, Yale University, New Haven, CT 06510 2283, USA
Lancet 376:367-87. 2010..Multifaceted, interdisciplinary approaches are urgently needed to achieve parity in health outcomes in HIV-infected drug users...
HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite studyFrederick L Altice
Yale University School of Medicine, New Haven, CT, USA
J Acquir Immune Defic Syndr 56:S22-32. 2011..Having opioid dependence and HIV infection are associated with poor HIV-related treatment outcomes...
Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trialDuncan Smith Rohrberg Maru
Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT, USA
J Acquir Immune Defic Syndr 50:176-81. 2009....
Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trialFrederick L Altice
Yale University AIDS Program, Yale University, New Haven, CT 06510 2283, USA
Clin Infect Dis 45:770-8. 2007..Directly administered antiretroviral therapy (DAART) is one approach to improve treatment adherence among human immunodeficiency virus (HIV)-infected drug users...
Initiation, adherence, and retention in a randomized controlled trial of directly administered antiretroviral therapyDuncan Smith Rohrberg Maru
Yale University AIDS Program, 135 College Street, Suite 323, New Haven, CT 06510 2283, USA
AIDS Behav 12:284-93. 2008..The presence of depression and the lack of willingness to travel greater than four blocks to receive DAART predicted time-to-discontinuation...
Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the communitySandra A Springer
Yale AIDS Program, Yale University School of Medicine, New Haven, Connecticut 06510-2283, USA
Clin Infect Dis 38:1754-60. 2004..More effective community-release programs are needed for incarcerated patients with HIV disease...
A prospective controlled trial of routine opt-out HIV testing in a men's jailRavi Kavasery
Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, Connecticut, United States of America
PLoS ONE 4:e8056. 2009..The objective of this study was to evaluate the optimal time to routinely HIV test newly incarcerated jail detainees using an opt-out strategy...
Clinical care of the HIV-infected drug userR Douglas Bruce
Yale University AIDS Program, Yale University School of Medicine, New Haven, CT 06510, USA
Infect Dis Clin North Am 21:149-79, ix. 2007....
Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populationsDuncan Smith Rohrberg Maru
Yale AIDS Program, Yale University School of Medicine, New Haven, Connecticut, USA
Clin Infect Dis 47:952-61. 2008..Data are lacking on outcomes of treatment with pegylated interferon plus ribavirin (PEG-RBV) in correctional settings...
Comparison of tuberculin skin testing reactivity in opioid-dependent patients seeking treatment with methadone versus buprenorphine: policy implications for tuberculosis screeningRyan K Schwarz
Department of Medicine, Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, Connecticut, USA
Am J Drug Alcohol Abuse 35:439-44. 2009..Currently, tuberculin skin testing (TST) is recommended for patients enrolling in methadone maintenance treatment (MMT), but not for those enrolling in buprenorphine maintenance treatment (BMT)...
Integration and co-location of HIV/AIDS, tuberculosis and drug treatment servicesLaurie Sylla
Yale University AIDS Programme, 135 College Street, Suite 323, New Haven, CT 06510, United States
Int J Drug Policy 18:306-12. 2007....
Routine opt-out HIV testing strategies in a female jail setting: a prospective controlled trialRavi Kavasery
Yale University School of Medicine, Section of Infectious Diseases, AIDS Program, New Haven, Connecticut, United States of America
PLoS ONE 4:e7648. 2009..Ten million Americans enter jails annually. The objective was to evaluate new CDC guidelines for routine opt-out HIV testing and examine the optimal time to implement routine opt-out HIV testing among newly incarcerated jail detainees...
Impact of enhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug usersDuncan Smith-Rohrberg
Yale University AIDS Program, New Haven, Connecticut 06510-2283, USA
J Acquir Immune Defic Syndr 43:S48-53. 2006..These results suggest the potential utility of integrating these services into DAART interventions (DAART-Plus) targeting HIV-infected drug users with problematic adherence...
Models for integrating buprenorphine therapy into the primary HIV care settingSanjay Basu
AIDS Program, Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510, USA
Clin Infect Dis 42:716-21. 2006..The key barriers against effective integration of buprenorphine maintenance therapy and primary HIV services are discussed, and we suggest several mechanisms to overcome such obstacles...
Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminasesRobert D Bruce
Yale University AIDS Program, New Haven, Connecticut 06511, USA
Am J Drug Alcohol Abuse 33:869-74. 2007..Previous reports in the literature have suggested hepatotoxicity with buprenorphine tempering initial enthusiasm of the safety of buprenorphine in HCV-infected patients...
Directly administered antiretroviral therapy for HIV-infected drug users does not have an impact on antiretroviral resistance: results from a randomized controlled trialDuncan Smith Rohrberg Maru
Yale University AIDS Program, Yale University School of Medicine, New Haven, CT 06510 2283, USA
J Acquir Immune Defic Syndr 46:555-63. 2007..Directly administered antiretroviral therapy (DAART) is an effective intervention that improves clinical outcomes among HIV-infected drug users. Its effects on antiretroviral drug resistance, however, are unknown...
Case series of buprenorphine injectors in Kuala Lumpur, MalaysiaR Douglas Bruce
AIDS Program, Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut 06510 2283, USA
Am J Drug Alcohol Abuse 34:511-7. 2008..Prospective cohort studies, rather than hospital-derived samples, are needed to better understand the safety of buprenorphine injection...
Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian marketR Douglas Bruce
Yale University AIDS Program, New Haven, Connecticut, USA
Am J Drug Alcohol Abuse 35:68-72. 2009..To address this concern, co-formulation of buprenorphine/naloxone (BPN/NLX) replaced buprenorphine alone in Malaysia in December 2006...
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxoneR Douglas Bruce
Yale University AIDS Program, 135 College Street, Suite 323, New Haven, CT, United States
Drug Alcohol Depend 105:234-9. 2009..BUP/NLX and TPV/r should therefore be used cautiously to avoid decreased efficacy of TPV in patients taking these agents concomitantly...
HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implicationsR Douglas Bruce
Yale University AIDS Program, New Haven, CT 06510 2283, United States
Int J Drug Policy 18:326-8. 2007..Until buprenorphine maintenance therapy (BMT) was introduced, few effective strategies aimed at achieving reduction in illicit drug use were available as a conduit to anti-retroviral therapy (ARV) among IDUs...
Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatmentSANDRA ANN SPRINGER
Yale AIDS Program, 135 College Street, Suite 323, New Haven, CT 06510, USA
J Urban Health 87:592-602. 2010..Future randomized controlled trials are needed to affirm its benefit in this highly vulnerable population...
Preparing for highly active antiretroviral therapy rollout in rural South Africa: an assessment using the information, motivation, and behavioral skills modelMargo D Simon
AIDS Program, Yale University School of Medicine, New Haven, CT, USA
AIDS Care 22:462-74. 2010..Community-based assessments are urgently needed as HAART rollouts continue. Adaptation of this IMB-based survey may better inform efforts to enhance HAART-program implementation in resource-limited settings globally...
Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavirRobert Douglas Bruce
Department of Medicine, Yale University AIDS Program, New Haven, CT, USA
J Acquir Immune Defic Syndr 54:511-4. 2010..This study was conducted to examine the pharmacokinetic interactions between buprenorphine/naloxone (BUP/NLX) and lopinavir/ritonavir (LPV/r) in HIV-seronegative subjects chronically maintained on BUP/NLX...
Managing HIV/AIDS in correctional settingsSandra A Springer
Yale University School of Medicine, Yale AIDS Program, Section of Infectious Diseases, 135 College Street, Suite 323, New Haven, CT 06510, USA
Curr HIV/AIDS Rep 2:165-70. 2005....
Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxoneDavid A Fiellin
Departments of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520 8093, USA
J Acquir Immune Defic Syndr 56:S33-8. 2011..Buprenorphine/naloxone allows the integration of opioid dependence and HIV treatment...
Pharmacological pain control for human immunodeficiency virus-infected adults with a history of drug dependenceSanjay Basu
Yale University AIDS Program, Yale University School of Medicine, New Haven, CT 06511, USA
J Subst Abuse Treat 32:399-409. 2007....
Attitudes toward and beliefs about prenatal HIV testing policies and mandatory HIV testing of newborns among drug usersOdicie Fielder
Yale University School of Medicine, New Haven, Connecticut, USA
AIDS Public Policy J 20:74-91. 2005..We also examined to what extent negative experiences and stigmatization affected attitudes toward HIV testing...
Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practiceR Douglas Bruce
Yale University AIDS Program, 135 College Street, New Haven, CT 06511, USA
J Acquir Immune Defic Syndr 41:563-72. 2006..Global access to opioid agonist therapy and HIV treatment is expanding but when concurrently used, problematic pharmacokinetic drug interactions can occur...
Antiretroviral treatment regimen outcomes among HIV-infected prisonersSandra A Springer
Yale University AIDS Program, New Haven, CT 06510 2283, USA
HIV Clin Trials 8:205-12. 2007..Despite the high prevalence of HIV in correctional settings, the duration of therapy and response to various highly active antiretroviral therapy (HAART) regimens in this setting is unknown...
Observations on implementing routine HIV testing in jailsRavi Kavasery
Yale University School of Medicine, Yale University AIDS Program, New Haven, Connecticut 06510-2283, USA
AIDS Patient Care STDS 21:715-6; author reply 717. 2007
HIV testing in correctional institutions: evaluating existing strategies, setting new standardsSanjay Basu
AIDS Program, Section of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, in New Haven, Connecticut, USA
AIDS Public Policy J 20:3-24. 2005..Jails present added complexities because of their shorter stay with respect to prisons, and testing, treatment, and counseling policies must be adapted to these settings...
Human immunodeficiency virus infection with human granulocytic ehrlichiosis complicated by symptomatic lactic acidosisSandra A Springer
Yale University AIDS Program, Yale New Haven Hospital and Yale School of Medicine, New Haven, CT, 06510 2283, USA
Clin Infect Dis 36:e162-4. 2003..To date, this is the first presentation of symptomatic hyperlactatemia in a patient with HIV infection and HGE...
Adherence to hepatitis B virus vaccination at syringe exchange sitesFrederick L Altice
Yale University AIDS Program, 135 College Street, Suite 323, New Haven, CT 06510 2283, USA
J Urban Health 82:151-61. 2005..Trust engendered by and mutual respect afforded by such programs result in repeated encounters by active IDUs over time...
Cost-effectiveness of HIV screening for incarcerated pregnant womenStephen Resch
Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT 06510-2283, USA
J Acquir Immune Defic Syndr 38:163-73. 2005..In settings where HIV screening policies are not in place, however, the implementation of RPS can be expected to significantly reduce pediatric HIV cases and net health care expenditures...
Hepatitis B virus infection in US correctional facilities: a review of diagnosis, management, and public health implicationsShaili Gupta
Section of Infectious Diseases, AIDS Program, Yale University School of Medicine, New Haven, CT 06510 2283, USA
J Urban Health 86:263-79. 2009..We present a review of diagnosis, prevention, and the recently streamlined treatment guidelines for management of HBV infection in correctional settings, and discuss the implications and public health impact of these measures...
The impact of needle exchange-based health services on emergency department useHarold A Pollack
School of Public Health, University of Michigan, Ann Arbor 48109 2029, USA
J Gen Intern Med 17:341-8. 2002....
Increasing drug users' adherence to HIV treatment: results of a peer-driven intervention feasibility studyRobert S Broadhead
Department of Sociology, University of Connecticut, Storrs 06269 2068, USA
Soc Sci Med 55:235-46. 2002..Innovative mechanisms that harness drug users' peer pressure to promote positive behavioral changes deserve greater study...
Randomized, controlled trials of directly administered antiretroviral therapy for HIV-infected patients: questions about study population and analytical approachDuncan Smith-Rohrberg
Clin Infect Dis 43:1221-2; author reply 1222-3. 2006
The association between history of violence and HIV risk: a cross-sectional study of HIV-negative incarcerated women in ConnecticutAnita Ravi
Atlanta, GA, USA
Womens Health Issues 17:210-6. 2007....
Behavioral counseling content for optimizing the use of buprenorphine for treatment of opioid dependence in community-based settings: a review of the empirical evidenceMichael M Copenhaver
Department of Psychology, University of Connecticut, Storrs, Connecticut 06269, USA
Am J Drug Alcohol Abuse 33:643-54. 2007..Evidence points toward the use of behavioral counseling aimed at enhancing patients' motivation during treatment entry followed by an emphasis on improving coping/relapse prevention skills during the primary phase of treatment...
Strategies for primary HIV prevention that target behavioral changeSteven A Safren
Fenway Community Health and Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Clin Infect Dis 45:S300-307. 2007..Objective evidence of reductions in high-risk behavior in these 3 groups, which account for the majority of HIV transmissions in the United States, has critical implications for reducing the overall rate of new HIV infections...
Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavirR Douglas Bruce
AIDS 20:783-4. 2006
HIV control efforts should directly address incarcerationDuncan Smith-Rohrberg Maru
Lancet Infect Dis 7:568-9. 2007
Editorial comment: why treat three conditions when it is one patient?R Douglas Bruce
AIDS Read 13:378-9. 2003
Research Grants
- Prison Interventions and HIV Prevention CollaborationFREDERICK LEWIS ALTICE; Fiscal Year: 2010....
- Intervention of HIV, Drug Use and the Criminal Justice System in MalaysiaFREDERICK LEWIS ALTICE; Fiscal Year: 2010....
- Intervention of HIV, Drug Use and the Criminal Justice System in MalaysiaFrederick Altice; Fiscal Year: 2009....
- PS06-011, HIV Prevention Research with HIV+ Incarcerated PopulationsFrederick Altice; Fiscal Year: 2007....
- Enhancing Health Outcomes Among HIV+ Substance AbusersFrederick Altice; Fiscal Year: 2007..Therefore, if allowed the opportunity to decrease my current clinical and administrative responsibilities, I am likely to be able to achieve my short- and long-term career development goals. ..
- Directly Observed Therapy for Community-Released HIV-positive PrisonersFrederick Altice; Fiscal Year: 2007..It is therefore likely that the stated aim will be successfully accomplished, despite the challenges of working with prisoners and drug-using populations. ..
- Improving Health Outcomes for Released HIV+ PrisonersFrederick Altice; Fiscal Year: 2007....
- DIRECTLY OBSERVED ANTI RETROVIRAL THERAPY AMONG ACTIVE DFrederick Altice; Fiscal Year: 2004..Secondary measures of interest include quality of life measures, health care utilization and entry into drug treatment. ..
- HIV, Buprenorphine, and the Criminal Justice SystemFREDERICK LEWIS ALTICE; Fiscal Year: 2010..This proposal intends to improve health to the individual and to the community during the crucial period during transition from the prison to the community. ..
